Early gastric cancer
Prepared with OnCo (onco.cc/prep/early-gastric-cancer/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
13 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example Depth of invasion, ulceration and size, Differentiated versus undifferentiated histology, Lymphovascular invasion and margin status on the resected specimen, Helicobacter pylori status, Intestinal metaplasia and atrophy extentfor surveillance intervals), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (within endoscopic criteria), which of the standard options do you recommend and why?
- 6.For my situation (non-curative resection or outside criteria), which of the standard options do you recommend and why?
- 7.For my situation (after resection), which of the standard options do you recommend and why?
- 8.For my situation (screening), which of the standard options do you recommend and why?
- 9.Are there clinical trials I could join, for example of Endoscopic resection (EMR / ESD), Robotic & minimally invasive surgery, Liquid biopsy (ctDNA), MRD / molecular residual disease testing?
- 10.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 11.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
- 12.I read that “Western countries have no screening and diagnose most gastric cancers late”. How does that affect my plan?
- 13.I read that “Predicting nodal spread in submucosal tumours to spare more patients surgery”. How does that affect my plan?
The words I may hear
- Screening: Testing people who have no symptoms to catch cancer, or its precursors, early enough to cure.
- Gastrectomy: Removing part (subtotal) or all (total) of the stomach for stomach cancer, with the bowel joined to what remains.
- Lymphadenectomy (lymph node dissection): Surgically removing the lymph nodes that drain a tumour, both to stage the cancer and to clear any spread.
- Endoscopy (EGD, EUS, ERCP): Looking inside a hollow organ with a camera on a flexible tube, taking biopsies and sometimes treating on the spot.
Tests and results to bring
Biomarker results to ask for: Depth of invasion, ulceration and size (endoscopic resection criteria), Differentiated versus undifferentiated histology, Lymphovascular invasion and margin status on the resected specimen (eCura risk), Helicobacter pylori status, Intestinal metaplasia and atrophy extent (Kimura-Takemoto, OLGA) for surveillance intervals.
Scans and tests linked to this cancer: Endoscopic resection (EMR / ESD), Liquid biopsy (ctDNA), MRD / molecular residual disease testing.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Screening: Biennial endoscopy from age 40 in Korea and from 50 in Japan; risk-based screening for people of East Asian origin and with atrophic gastritis elsewhere. (Screening, Endoscopy (EGD, EUS, ERCP))
- Within endoscopic criteria: Endoscopic submucosal dissection with en bloc resection and pathological assessment of depth, margins and lymphovascular invasion. (Endoscopic resection (EMR / ESD), Endoscopy (EGD, EUS, ERCP))
- Non-curative resection or outside criteria: Gastrectomy with D1+ lymph node dissection, laparoscopic or robotic (KLASS-01, JCOG0912). (Gastrectomy, Lymphadenectomy (lymph node dissection), Robotic & minimally invasive surgery, Japan Clinical Oncology Group (JCOG))
- After resection: Helicobacter pylori eradication and annual endoscopic surveillance for metachronous cancer; no adjuvant chemotherapy for stage I. (Endoscopy (EGD, EUS, ERCP), Chemoprevention & risk-reducing surgery)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.